Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.


Malmström A., Grønberg B., Marosi C., Stupp R., Frappaz D., Schultz H., et al.

The Lancet. Oncology, cilt.13, ss.916-26, 2012 (SCI İndekslerine Giren Dergi)